Correspondence 0001178913-23-002788 from RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd.
Date: Aug. 9, 2023 · CIK: 0001553846 · Accession: 0001178913-23-002788
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273709
Letter
RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv, 6473921, Israel
August 9, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re:
RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed August 4, 2023
File No. 333-273709
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form F-3 (File No. 333-273709) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on August 11, 2023, or as soon thereafter as practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Jayun Koo at (212) 659-7300, and that such effectiveness also be confirmed in writing.
Very truly yours,
REDHILL BIOPHARMA LTD.
Show Raw Text
CORRESP
1
filename1.htm
RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv, 6473921, Israel
August 9, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re:
RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed August 4, 2023
File No. 333-273709
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as
amended, RedHill Biopharma Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form F-3 (File No. 333-273709)
(the “Registration Statement”) be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on August 11, 2023, or as soon thereafter as practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by
telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Jayun Koo at (212) 659-7300, and that such effectiveness also be confirmed in writing.
Very truly yours,
REDHILL BIOPHARMA LTD.
By:
/s/ Dror Ben-Asher
Dror Ben-Asher
Chief Executive Officer and Chairman of the Board of Directors
cc:
Rick A. Werner, Esq., Haynes and Boone, LLP
Jayun Koo, Esq., Haynes and Boone, LLP